Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Provided By GlobeNewswire
Last update: Mar 31, 2025
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis
Read more at globenewswire.com
